BBOT BridgeBio Oncology Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 11, 2026
$3.89
· of 52w range
· above low
· to high
$3.7952w low
$14.8752w high
Market Cap (MRQ)
$312M
P/E
-0.9
EPS
$-4.30
your badges
52W Range
$4–$15
Analyst Rating
BUY
Price Target
$25
P/E
-0.9
ROE
-146.2%
Net Profit Margin
·
Your badge strip is empty — pin a metric anywhere on this page.
BBOT Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$3.89
Market Cap (MRQ)
$312M
P/E
-0.9
EPS
$-4.30
ROE
-146.2%
Debt/Equity
0.0
52W Range
$4–$15
BBOT Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
EPS$-4.302024-12-31 → 2025-12-31
Free Cash Flow$-114M2025-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | BBOT | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | -0.9 | · | · | · | |
| P/B (MRQ) | 1.0 | · | 2.2 | Undervalued | |
| EV / EBITDA | 0.8 | · | · | · | |
| Price / FCF (TTM) | -1.6 | · | · | · | |
| Price / Cash Flow (TTM) | -1.6 | · | · | · | |
| EV / FCF | 1.0 | · | · | · | |
| Price / Tangible Book | 0.8 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | BBOT | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| ROA | -43.8% | · | -49.3% | In line | |
| ROE | -146.2% | · | -115.5% | Weak |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | BBOT | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity | 0.0 | · | · | · | |
| Current Ratio (MRQ) | 4.7 | · | 5.1 | Low liquidity | |
| Quick Ratio | 12.1 | · | 4.2 | In line |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-43.4%
Next Report
Nov 09, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Jul 29, 2026 | $-0.71 | $-0.58 | -23.1% |
| March 31, 2026 | May 7, 2026 | $-0.53 | $-0.54 | 1.4% |
| Dec. 31, 2025 | $-0.49 | $-0.53 | 7.1% | |
| Sept. 30, 2025 | $-1.03 | $-0.40 | -159.1% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| R&D Expense | $121M | $73M | · | |
| SG&A Expense | $25M | $8M | $41.7K | |
| Operating Expenses | $146M | $81M | · | |
| Operating Income | $-146M | $-81M | $-41.7K | |
| Interest Income | $11M | $6M | · | |
| Other Non-op | $-35.0K | $0 | · | |
| Income Tax | $0 | $0 | · | |
| Net Income | $-134M | $-74M | $-41.7K | |
| EPS (Basic) | $-4.30 | $-5756.41 | · | |
| EPS (Diluted) | $-4.30 | $-5756.41 | · | |
| Shares (Basic) | 31,144,775 | 12,903 | · | |
| Shares (Diluted) | 31,144,775 | 12,903 | · | |
| EBITDA | $-146M | $-584.4K | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Cash & Equivalents | $374M | $31M | $0 | |
| Short-term Investments | $52M | $125M | · | |
| Prepaid Expense | $7M | $3M | · | |
| Current Assets | $432M | $159M | · | |
| PP&E (Net) | $956.0K | $490.0K | · | |
| Other Non-current Assets | $13M | $5M | · | |
| Total Assets | $448M | $164M | $332.9K | |
| Accounts Payable | $1M | $3M | · | |
| Accrued Liabilities | · | $119.7K | $15.0K | |
| Short-term Debt | $534.0K | $483.0K | $70.1K | |
| Current Liabilities | $35M | $20M | $396.5K | |
| Capital Leases | $2M | $0 | · | |
| Total Liabilities | $37M | $20M | $396.5K | |
| Total Debt | $534.0K | · | · | |
| Common Stock | $8.0K | $0 | · | |
| Paid-in Capital | $768M | $44M | $24.5K | |
| Retained Earnings | $-357M | $-223M | $-88.6K | |
| AOCI | $16.0K | $348.0K | · | |
| Stockholders' Equity | $411M | $-179M | $-116M | |
| Liabilities + Equity | $448M | $164M | $332.9K | |
| Shares Outstanding | 79,991,768 | 28,415 | · |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Stock-based Comp | $6M | $4M | · | |
| Deferred Tax | $0 | $0 | · | |
| Operating Cash Flow | $-114M | $-55M | · | |
| CapEx | $606.0K | $49.0K | · | |
| Investing Cash Flow | $73M | $-121M | · | |
| Stock Issued | $112M | · | · | |
| Net Stock Activity | $112M | · | · | |
| Financing Cash Flow | $383M | $206M | · | |
| Free Cash Flow | $-114M | · | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| ROA | -43.8% | 7.8% | · | |
| ROE | -146.2% | -9.3% | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Current Ratio | 12.3 | 10.4 | · | |
| Quick Ratio | 12.1 | 9.1 | · | |
| Debt / Equity | 0.0 | · | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Book Value / Share | $5.14 | · | · | |
| Cash Flow / Share | $-3.66 | · | · | |
| Cash / Share | $4.67 | · | · | |
| EPS (TTM) | $-4.30 | $-5756.41 | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Net Income TTM | $-134M | $-74M | · | |
| Market Cap | $1.00B | · | · | |
| Enterprise Value | $577M | · | · | |
| P/E | -2.9 | -0.0 | · | |
| P/B | 2.4 | · | · | |
| P / Tangible Book | 2.4 | · | · | |
| P / Cash Flow | -8.8 | · | · | |
| P / FCF | -8.7 | · | · | |
| EV / EBITDA | -4.0 | · | · | |
| EV / FCF | -5.0 | · | · | |
| Earnings Yield | -34.4% | -54823.0% | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $49M | $40M | $38M | $35M | $27M | $21M | $20M | $18M | · | · | |
| SG&A Expense | $11M | $6M | $7M | $14M | $3M | $3M | $6M | $2M | $152.3K | $66.7K | |
| Operating Expenses | $60M | $46M | $43M | $49M | $30M | $23M | $22M | $20M | · | · | |
| Operating Income | $-60M | $-46M | $-93M | $-49M | $-30M | $-23M | $-61M | $-20M | $-152.3K | $-66.7K | |
| Interest Income | $4M | $4M | $4M | $3M | $2M | $2M | $255.2K | $2M | $2M | $1M | |
| Other Non-op | $-14.0K | $-94.0K | $-4M | $-30.0K | $-8.0K | $-2.0K | $-4M | $0 | $2M | $1M | |
| Income Tax | $0 | · | $0 | $0 | $0 | $0 | $0 | $0 | · | · | |
| Net Income | $-56M | $-42M | $-39M | $-45M | $-28M | $-22M | $-20M | $-17M | $-22M | $-15M | |
| EPS (Basic) | $-705.20 | $-526.11 | $2.19 | $-1.03 | $-566.46 | $-54.23 | $-833.69 | $-1562.18 | · | · | |
| EPS (Diluted) | $-705.20 | $-526.11 | $2.19 | $-1.03 | $-566.46 | $-54.23 | $-833.69 | $-1562.18 | · | · | |
| Shares (Basic) | 80,054,000 | 80,032 | · | 43,491,085 | 50,198,000 | 406,723 | · | 11,089 | · | · | |
| Shares (Diluted) | 80,054,000 | 80,032 | · | 43,491,085 | 50,198,000 | 406,723 | · | 11,089 | · | · | |
| EBITDA | $-60M | $-46M | · | $-49M | $-1M | $-2M | · | $-146.9K | $-152.3K | $-66.7K |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $54M | $53M | $374M | $409M | $664.2K | $963.1K | $31M | $2M | $2M | $2M | |
| Short-term Investments | $172M | $200M | $52M | $60M | · | · | $125M | · | · | · | |
| Prepaid Expense | $16M | $14M | $7M | $7M | $62.5K | · | $3M | · | $11.3K | $16.3K | |
| Current Assets | $242M | $267M | $432M | $476M | $876.8K | $1M | $159M | $2M | $2M | $2M | |
| PP&E (Net) | $878.0K | $938.0K | $956.0K | $827.0K | · | · | $490.0K | · | · | · | |
| Other Non-current Assets | $13M | $11M | $13M | $5M | · | · | $5M | · | · | · | |
| Total Assets | $377M | $418M | $448M | $485M | $197M | $196M | $164M | $192M | $190M | $188M | |
| Accounts Payable | $7M | $12M | $1M | $4M | $3M | · | $3M | · | · | · | |
| Accrued Liabilities | · | · | · | · | · | $2M | · | $126.7K | $79.1K | $23.3K | |
| Short-term Debt | · | $716.0K | $534.0K | $691.0K | · | · | $483.0K | · | · | · | |
| Current Liabilities | $52M | $43M | $35M | $36M | $3M | $2M | $20M | $126.7K | $79.1K | $23.3K | |
| Capital Leases | $2M | $2M | $2M | $2M | · | · | $0 | · | · | · | |
| Total Liabilities | $54M | $45M | $37M | $38M | $8M | $7M | $20M | $6M | $6M | $6M | |
| Total Debt | · | $716.0K | · | $691.0K | · | · | · | · | · | · | |
| Common Stock | $8.0K | $8.0K | $8.0K | $8.0K | · | · | $0 | · | · | $51 | |
| Paid-in Capital | $779M | $772M | $768M | $764M | · | · | $44M | · | · | · | |
| Retained Earnings | $-455M | $-399M | $-357M | $-318M | $-7M | $-6M | $-223M | $-4M | $-3M | $-3M | |
| AOCI | $-959.0K | $-981.0K | $16.0K | $36.0K | · | · | $348.0K | · | · | · | |
| Stockholders' Equity | $323M | $372M | $411M | $447M | $-7M | $-6M | $-179M | $-4M | $-3M | $-3M | |
| Liabilities + Equity | $377M | $418M | $448M | $485M | $197M | $196M | $164M | $192M | $190M | $188M | |
| Shares Outstanding | 80,115,002 | 80,088,931 | 79,991,768 | 79,196,710 | · | · | 28,415 | · | · | · |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $7M | $4M | $3M | $3M | $36.0K | $627.0K | $4M | $77.4K | $77.4K | $39.4K | |
| Operating Cash Flow | $-44M | $-36M | $-42M | $-71M | $-298.9K | $-20M | $-15M | $-39M | $-29.1K | $-618.0K | |
| CapEx | $47.0K | $24.0K | $73.0K | $140.0K | $231.0K | $162.0K | $10.0K | · | · | · | |
| Investing Cash Flow | $46M | $-285M | $8M | $41M | $10M | $15M | $26M | $38M | $0 | $-184M | |
| Stock Issued | $0 | $112M | $-9M | · | · | · | · | · | · | · | |
| Net Stock Activity | · | $112M | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $37.0K | $295.0K | $-586.0K | $365M | $19M | $-404.0K | $52.0K | $20M | $0 | $186M | |
| Free Cash Flow | · | $-36M | · | · | · | · | · | · | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -19.7% | -13.7% | · | -13.2% | 0.47% | -0.25% | · | 2.4% | 2.3% | 1.2% | |
| ROE | -35.8% | -23.0% | · | -20.2% | -17.2% | 10.4% | · | -132.7% | -131.2% | -68.3% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.7 | 6.2 | · | 13.3 | 0.3 | 0.7 | · | 16.1 | 26.2 | 90.4 | |
| Quick Ratio | 4.4 | 5.8 | · | 13.1 | 0.3 | 0.5 | · | 14.1 | 22.9 | 79.0 | |
| Debt / Equity | · | 0.0 | · | 0.0 | · | · | · | · | · | · |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $4.03 | $4.65 | · | $5.64 | · | · | · | · | · | · | |
| Cash Flow / Share | · | $-448.78 | · | · | · | · | · | · | · | · | |
| Cash / Share | $0.67 | $0.66 | · | $5.16 | · | · | · | · | · | · | |
| EPS (TTM) | $-1230.15 | $-1091.41 | · | $-1455.41 | $-3016.56 | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-182M | $-154M | · | $-115M | $-88M | $-81M | · | · | · | · | |
| Market Cap | $610M | $717M | · | $917M | · | · | · | · | · | · | |
| Enterprise Value | · | $465M | · | $450M | · | · | · | · | · | · | |
| P/E | -0.0 | -0.0 | · | -0.0 | -0.0 | · | · | · | · | · | |
| P/B | 1.9 | 1.9 | · | 2.1 | · | · | · | · | · | · | |
| P / Tangible Book | 1.9 | 1.9 | · | 2.1 | · | · | · | · | · | · | |
| P / Cash Flow | · | -20.0 | · | · | · | · | · | · | · | · | |
| Earnings Yield | -16143.7% | -12194.5% | · | -12568.3% | -28404.5% | · | · | · | · | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net Income | $-134M | $-74M | $-41.7K |
| Diluted EPS | $-4.30 | $-5756.41 | · |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Debt / Equity | 0.0 | · | · |
| Current Ratio | 12.3 | 10.4 | · |
| Quick Ratio | 12.1 | 9.1 | · |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Free Cash Flow | $-114M | · | · |
Institutional owners (13F) 64 filers · $456.8M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
64
Value held
$456.8M
New positions
16
Exited positions
18
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 16 (-5 vs prior Q) | 18 (+12 vs prior Q) | 19 (-1 vs prior Q) | 14 (+3 vs prior Q) | +1.7M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| Cormorant Asset Management, LP | $136,234,886 | 17,878,594 | 29.83% | Shares |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $37,227,099 | 4,885,446 | 8.15% | Shares |
| Omega Fund Management, LLC | $25,067,217 | 3,289,661 | 5.49% | Shares |
| Alphabet Inc. | $21,512,220 | 2,823,126 | 4.71% | Shares |
| EcoR1 Capital, LLC | $21,512,220 | 2,823,126 | 4.71% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $21,254,481 | 2,789,302 | 4.65% | Shares |
| ENAVATE SCIENCES GP, LLC | $20,017,329 | 2,626,946 | 4.38% | Shares |
| CITADEL ADVISORS LLC | $19,947,841 | 2,617,827 | 4.37% | Shares |
| NOVO HOLDINGS A/S | $17,145,000 | 2,250,000 | 3.75% | Shares |
| BlackRock, Inc. | $16,413,785 | 2,154,040 | 3.59% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $15,283,045 | 2,005,649 | 3.35% | Shares |
| Laurion Capital Management LP | $15,260,582 | 2,002,701 | 3.34% | Shares |
| ARMISTICE CAPITAL, LLC | $13,441,680 | 1,764,000 | 2.94% | Shares |
| VANGUARD GROUP INC | $9,904,510 | 791,095 | 2.17% | Shares |
| STATE STREET CORP | $7,898,656 | 1,036,569 | 1.73% | Shares |
| Aisling Capital Management LP | $7,757,297 | 1,018,018 | 1.70% | Shares |
| Opaleye Management Inc. | $5,334,000 | 700,000 | 1.17% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $4,744,649 | 622,351 | 1.04% | Shares |
| Granahan Investment Management, LLC | $4,255,968 | 558,526 | 0.93% | Shares |
| SPHERA FUNDS MANAGEMENT LTD. | $3,512,706 | 460,985 | 0.77% | Shares |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $3,048,000 | 400,000 | 0.67% | Shares |
| ROYCE & ASSOCIATES LP | $2,933,250 | 384,941 | 0.64% | Shares |
| Catalio Capital Management, LP | $2,426,261 | 318,407 | 0.53% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $2,221,398 | 291,522 | 0.49% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $2,183,267 | 286,518 | 0.48% | Shares |
| Casdin Capital, LLC | $2,151,217 | 282,312 | 0.47% | Shares |
| Ensign Peak Advisors, Inc | $2,084,299 | 273,530 | 0.46% | Shares |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $1,872,418 | 244,441 | 0.41% | Shares |
| FMR LLC | $1,833,272 | 240,587 | 0.40% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $1,456,578 | 191,152 | 0.32% | Shares |
| NORTHERN TRUST CORP | $1,420,993 | 186,482 | 0.31% | Shares |
| Sio Capital Management, LLC | $995,385 | 130,628 | 0.22% | Shares |
| UBS Group AG | $873,671 | 114,655 | 0.19% | Shares |
| MILLENNIUM MANAGEMENT LLC | $803,758 | 105,480 | 0.18% | Shares |
| GOLDMAN SACHS GROUP INC | $777,888 | 102,085 | 0.17% | Shares |
| MOORE CAPITAL MANAGEMENT, LP | $762,000 | 100,000 | 0.17% | Shares |
| Brevan Howard Capital Management LP | $690,714 | 88,895 | 0.15% | Shares |
| Palumbo Wealth Management LLC | $652,455 | 85,624 | 0.14% | Shares |
| BANK OF AMERICA CORP /DE/ | $587,807 | 77,140 | 0.13% | Shares |
| Jump Financial, LLC | $472,440 | 62,000 | 0.10% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $446,532 | 58,600 | 0.10% | Shares |
| Avidity Partners Management LP | $334,160 | 43,853 | 0.07% | Shares |
| TD Asset Management Inc | $325,603 | 42,730 | 0.07% | Shares |
| Virtus Investment Advisers, LLC | $321,716 | 42,220 | 0.07% | Shares |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $213,238 | 27,984 | 0.05% | Shares |
| TWO SIGMA INVESTMENTS, LP | $201,816 | 26,485 | 0.04% | Shares |
| Rafferty Asset Management, LLC | $172,258 | 22,606 | 0.04% | Shares |
| CITIGROUP INC | $151,425 | 19,872 | 0.03% | Shares |
| Squarepoint Ops LLC | $149,824 | 19,662 | 0.03% | Shares |
| Vanguard Global Advisers, LLC | $138,402 | 18,163 | 0.03% | Shares |
Activists & 5%+ owners 3 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Bihua Chen, Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare Fund V, LP, Cormorant Private Healthcare GP V, LLC, Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Helix Holdings II LLC | July 6, 2026 | 22.32% | Amendment | · | SEC |
| BridgeBio Pharma LLC, BridgeBio Pharma, Inc. | Aug. 18, 2025 | 17.50% | Initial filing | Board campaign | SEC |
| Helix Holdings II LLC, Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Bihua Chen ×3 filings | Aug. 13, 2025 | 22.60% | Amendment | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 17 insiders · 5 officers · 10 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Pedro Beltran | President and CEO | July 1, 2026 F | 44,576 | 0 | 0 | $0 |
| Eli M. Wallace | Chief Executive Officer | Jan. 1, 2026 A | · | 0 | 0 | $0 |
| Idan Elmelech | COO & Principal Financial Ofcr | July 1, 2026 F | 14,495 | 0 | 0 | $0 |
| Marc Cobo | Principal Accounting Officer | Sept. 10, 2026 A | 14,141 | 0 | 0 | $0 |
| Yong Ben | Chief Med & Dev Officer | July 1, 2026 F | 44,576 | 0 | 0 | $0 |
| Chen Bihua | Director | July 1, 2026 J | 6,083,221 | 0 | 0 | $0 |
| Peter F Lebowitz | Director | June 16, 2026 A | · | 0 | 0 | $0 |
| Raymond J. Kelleher | Director | June 16, 2026 A | · | 0 | 0 | $0 |
| Praveen P. Tipirneni | Director | June 16, 2026 A | · | 0 | 0 | $0 |
| Neil Kumar | Director | June 16, 2026 A | · | 0 | 0 | $0 |
| Jake Bauer | Director | June 16, 2026 A | · | 0 | 0 | $0 |
| Frank Mccormick | Director | June 16, 2026 A | · | 0 | 0 | $0 |
| Helix Holdings II LLC | Director | Feb. 8, 2025 J | 509,000 | 0 | 0 | $0 |
| Uneek Mehra | · | April 1, 2026 F | 22,806 | 0 | 0 | $0 |
| Albert A Holman III | · | Aug. 11, 2025 M | 30,000 | 0 | 0 | $0 |
| Mark C. Mckenna | · | Aug. 11, 2025 M | 30,000 | 0 | 0 | $0 |
| John P. Schmid | · | Aug. 11, 2025 M | 30,000 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 6 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0.70% | 40,107 NS | July 31, 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.05% | 27,634 NS | July 31, 2026 | N-PORT |
| IBB · iShares Trust | 0.02% | 338,248 SH | Sept. 11, 2026 | Daily |
| PWS · Pacer Funds Trust | 0.01% | 378 NS | July 31, 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 549,132 SH | Aug. 19, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 1,422,900 SH | Aug. 19, 2026 | Daily |
BBOT Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 17 analysts
BUY
Median target
$22.00
+465.6%
6 35.3%
Strong Buy
10 58.8%
Buy
1 5.9%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
11 analysts · 2026-10-03Mean target $24.55 +531.0%
← Below all targets
Current price $3.89
Low$15.00
Mean$24.55
High$50.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| BBOT | $1.00B | -2.9 | · | · | -146.2% | · |
| ARTV | · | -1.3 | -99.2% | · | · | · |
| BNTC | $460M | -13.7 | · | · | -25.0% | · |
| INDP | $6M | -0.1 | · | · | -2820.8% | · |
| SCTX | · | · | · | · | · | · |
| EBS | $644M | 13.3 | -28.8% | 7.1% | 9.9% | · |
| CABA | $220M | -1.0 | · | · | -115.5% | · |
| LRMR | $317M | -2.2 | · | · | -167.4% | · |
| IPSC | $87M | -7.1 | 1556.8% | -8.8% | -5.2% | · |
| PRLD | · | -2.2 | 73.4% | -819.6% | -137.7% | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 11, 2026